Golden Retriever

Veterinary Oncology Development Strategy 

Studies evaluating our lead veterinary immunotherapy candidate, MIE-201, in canine companion animals with multiple tumor types have consistently demonstrated immune activation, antitumor activity, increased survival and no signs of toxicity or adverse events. We plan to expand on these promising data by advancing MIE-201 into larger canine efficacy and safety field studies. Our veterinary management team is currently coordinating with regulatory authorities to develop an efficient and effective strategy to potentially advance MIE-201 toward conditional approval for canine cancers.

Veterinary Immuno-Oncology Program: Status and Plans

Candidate

Indication

Administration

Preclinical 

Proof of Concept

Exploratory Studies

Efficacy

Field Studies

Safety

Field Studies

2022 - 2023 Plans

MIE-201

Solid Tumors

Intratumoral

Completed / Ongoing

Planned

Initiate Efficacy Field Studies;

Potential Safety Field Studies

Efficacy Field Study Objectives

  • Evaluate clinical dose

  • Identify immune activation relationship to dose level

  • Measure antitumor responses

  • Assess abscopal effects and durability of responses